Sommetrics Receives Health Canada Approval to Market New Sleep Apnea Therapy

aerSleepTM is the first device to use negative external air pressure to successfully treat obstructive sleep apnea

SAN DIEGO--()--Sommetrics, a company providing products and services to improve sleep quality, today announced that its aerSleepTM system has received a Health Canada Medical Device License, which allows this system to be marketed in Canada. aerSleep will soon be available by prescription to Canadians diagnosed with obstructive sleep apnea. Sleep apnea afflicts more than 20 percent of adults worldwide, and is linked to other serious health conditions, such as Type 2 diabetes, heart disease, stroke, and cognitive/mental disorders.

“It’s a validation of our technology and a vital step in our commercial growth, and lays the groundwork for achieving our mission of improving the quality of sleep for people worldwide.”

The aerSleep system utilizes Sommetrics’ proprietary aer+™ technology, which applies negative external pressure to gently maintain an open airway during sleep. The aerSleep system’s soft collar and integrated silent vacuum pump allows sleep in virtually all positions, has no hoses or mask, and is non-invasive, comfortable, highly portable, cordless, and easy to use and maintain.

“Obtaining Health Canada’s approval for aerSleep is a major milestone for us,” said Richard Rose, M.D., Sommetrics’ chief executive officer and board chair. “It’s a validation of our technology and a vital step in our commercial growth, and lays the groundwork for achieving our mission of improving the quality of sleep for people worldwide.”

Sommetrics’ patented aer+ technology addresses the need for a highly effective and tolerable treatment for both sleep apnea and chronic snoring. The global market for sleep apnea devices is an estimated $4.9 billion and is expected to reach $8.8 billion in 2023. This market expansion does not include the impact of new and innovative products such as the aerSleep system.

About Sommetrics

Sommetrics, a privately funded company based in San Diego, develops products and services aimed at enhancing health and well-being by improving sleep quality. The company’s proprietary aer+ technology targets disorders related to the narrowing of the airway during sleep, such as obstructive sleep apnea and chronic snoring. Sommetrics has an FDA-cleared and CE-marked acute care product, which addresses airway narrowing commonly caused by mild to moderate sedation. For more information, visit www.sommetrics.com and follow the company on Twitter, Facebook and LinkedIn.

Contacts

Sommetrics
Sarah Polk
(760) 295-5620 ext. 1010
media@sommetrics.com
www.sommetrics.com

Recent Stories

RSS feed for Sommetrics

Release Summary

aerSleepTM is the first device to use negative external air pressure to successfully treat obstructive sleep apnea

Sommetrics